BTG plc: Results of AGM
London, UK, 26 July 2006: BTG plc (LSE: BGC), the medical innovations company, is pleased to announce that at its Annual General Meeting on 26 July 2006 all resolutions were passed on a show of hands. The number of proxy votes lodged for each resolution prior to the meeting was as follows:
In accordance with Listing Rule 9.6.2, certified copies of the resolutions passed as special business at the Annual General Meeting will shortly be available for inspection at the UK Listing Authority's Document Viewing Facility, which is situated at: Financial Services Authority, 25 The North Colonnade, Canary Wharf, London E14 5HS.
As previously announced in the 2006 Annual Report & Accounts, with effect from the conclusion of the Annual General Meeting Malcolm Coster retired from the Board of the Company.
Director of Investor Relations
+44 (0)20 7575 1741
BTG in-licenses, develops and commercialises pharmaceuticals and other medical technologies. With a substantial and growing revenue stream of royalties and milestone payments from out-licensed products, BTG continues to strengthen its pipeline of preclinical and clinical development programmes. Active in the fields of oncology, diseases of ageing, neuroscience, drug repositioning and medical devices, BTG works from offices in London, Philadelphia and Osaka through a global partner network of healthcare companies and research organisations. For further information, visit: www.btgplc.com.Back to press releases